Menu Search
Equities

BioInvent International AB

  • Add to watchlist
  • Add to portfolio
  • Add an alert
BINV:STO

BioInvent International AB

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (SEK)25.10
  • Today's Change-0.95 / -3.65%
  • Shares traded56.42k
  • 1 Year change+2.45%
  • Beta0.3944
Data delayed at least 15 minutes, as of Feb 17 2026 11:34 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Financials data is unavailable for this security.

Inc stmt in SEKIncome statement in SEKView more

Year on year BioInvent International AB's revenues fell -37.47% from 71.46m to 44.69m. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a loss of 330.30m to a larger loss of 429.38m.
Gross margin--
Net profit margin-132.30%
Operating margin-142.19%
Return on assets-34.58%
Return on equity-38.42%
Return on investment-38.20%
More ▼

Cash flow in SEKView more

In 2024, BioInvent International AB increased its cash reserves by 67.53%, or 175.28m. Cash Flow from Investing totalled 564.35m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 380.61m for operations while cash used for financing totalled 8.46m.
Cash flow per share-4.62
Price/Cash flow per share--
Book value per share10.38
Tangible book value per share10.38
More ▼

Balance sheet in SEKView more

BioInvent International AB appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio7.40
Quick ratio7.31
Total debt/total equity0.0157
Total debt/total capital0.0154
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.